BOSTON SCIENTIFIC CORPORATION Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net
BOSTON SCIENTIFIC CORPORATION (BSX) reported Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net of $1.00 million for the 3-month period ending 2011-03-31, per its 10-Q filed 2011-05-05.
Discontinued › Income Statement › Other Income
us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet · last filed 2011-05-05
- BOSTON SCIENTIFIC CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2011-03-31 was $1.00M.
- BOSTON SCIENTIFIC CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2010-06-30 was $0.00.
- BOSTON SCIENTIFIC CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2009-12-31 was -$30.00M.
- BOSTON SCIENTIFIC CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for the quarter ending 2009-09-30 was -$1.00M.
- BOSTON SCIENTIFIC CORPORATION derivative instruments, gain (loss) recognized in income, ineffective portion and amount excluded from effectiveness testing, net for fiscal 2009 was -$32.00M.
| Period end | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 3 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 6 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 9 month | Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net 12 month |
|---|---|---|---|---|
| 2011-03-31 | $1.00M 10-Q · filed 2011-05-05 | |||
| 2010-06-30 | $0.00 10-Q · filed 2010-08-05 | $0.00 10-Q · filed 2010-08-05 | ||
| 2009-12-31 | -$30.00M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-17 | -$31.00M derived: sum of 2 quarters · filed 2011-02-17 | -$31.00M derived: sum of 3 quarters · filed 2011-02-17 | -$32.00M 10-K · filed 2011-02-17 |
| 2009-09-30 | -$1.00M 10-Q · filed 2010-11-05 | -$1.00M derived: sum of 2 quarters · filed 2010-11-05 | -$2.00M 10-Q · filed 2010-11-05 | |
| 2009-06-30 | $0.00 10-Q · filed 2010-08-05 | -$2.00M 10-Q · filed 2010-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BECTON DICKINSON & CO (BDX) | United States | $48.834B | 43.79 |
| 3M CO (MMM) | United States | $86.404B | 27.87 |
| DEXCOM INC (DXCM) | United States | $33.004B | 25.42 |
| WEST PHARMACEUTICAL SERVICES INC (WST) | United States | $26.288B | 43.14 |
| STRYKER CORP (SYK) | United States | $103.511B | 32.39 |
| Solventum Corp (SOLV) | United States | $15.085B | 9.16 |
| Penumbra Inc (PEN) | United States | $12.596B | 77.33 |
| BAXTER INTERNATIONAL INC (BAX) | United States | $12.139B | -10.35 |
| GLOBUS MEDICAL INC (GMED) | United States | $9.977B | 20.03 |
| INSULET CORP (PODD) | United States | $9.420B | 28.12 |